CRISM Therapeutics Corporation (LSE:CRTX), a healthcare and pharmaceuticals company, has announced a retail share offer aimed at raising up to £100,000. The offer consists of new ordinary shares priced at 9 pence each and forms part of the company’s broader funding strategy for its Phase 2 clinical trial evaluating irinotecan-ChemoSeed in patients with glioblastoma. The offer is open to UK investors and is being coordinated by SP Angel Corporate Finance LLP. Completion remains subject to the admission of the new shares to trading on AIM.
More about CRISM Therapeutics Corporation
CRISM Therapeutics Corporation is a UK-based clinical-stage biotech company focused on improving cancer treatment through localized, sustained chemotherapy delivery. Its lead technology, ChemoSeed, is designed for implantation directly into tumors or surgical margins—particularly in the treatment of glioblastoma—allowing therapeutic agents to bypass the blood–brain barrier and more effectively target cancerous tissue.
Leave a Reply